DaVita Venture Group

Pathalys is a clinical biopharmaceutical company that develops therapeutics that improve late-stage chronic kidney disease. Pathalys' initial focus will be on improving treatment for secondary hyperparathyroidism, which is an unmet need (SHPT). SHPT is a condition in which a disease outside of the parathyroid glands causes all of the parathyroid glands to swell and become hyperactive, producing an excessive amount of parathyroid hormone (PTH).

Xeltis is a clinical-stage medical device company focused on transforming cardiovascular treatment through innovative restorative technologies. The company has developed advanced polymer-based devices, including bioabsorbable heart valves and implantable small diameter blood vessels, intended for hemodialysis vascular access and coronary artery bypass graft surgery. These devices leverage proprietary technology to facilitate endogenous tissue restoration, allowing the body to naturally regenerate the complex structures being replaced. Xeltis emerged from the merger of two university spin-offs from the Netherlands and Switzerland and operates in both the Netherlands and the USA. The company is backed by several venture capital firms and has secured significant funding from the European Investment Bank and the European Innovation Council Accelerator. Currently, Xeltis is conducting ongoing clinical trials to advance its restorative cardiovascular solutions.

Dock Health is a HIPAA compliant task management and collaboration platform designed for healthcare. The company is focused on solving some of the most pressing issues in healthcare by making communication and collaboration easier through thoughtful design and simplicity. Dock is on a mission to solve the workflow challenges and inefficiencies for clinicians and their teams. Dock Health hopes to improve patient care by giving medical teams a reliable and secure system to ensure the work gets done. Founded in 2016, Dock Health is headquartered in Boston, Massachusetts.

Xeltis is a clinical-stage medical device company focused on transforming cardiovascular treatment through innovative restorative technologies. The company has developed advanced polymer-based devices, including bioabsorbable heart valves and implantable small diameter blood vessels, intended for hemodialysis vascular access and coronary artery bypass graft surgery. These devices leverage proprietary technology to facilitate endogenous tissue restoration, allowing the body to naturally regenerate the complex structures being replaced. Xeltis emerged from the merger of two university spin-offs from the Netherlands and Switzerland and operates in both the Netherlands and the USA. The company is backed by several venture capital firms and has secured significant funding from the European Investment Bank and the European Innovation Council Accelerator. Currently, Xeltis is conducting ongoing clinical trials to advance its restorative cardiovascular solutions.

Pathalys is a clinical biopharmaceutical company that develops therapeutics that improve late-stage chronic kidney disease. Pathalys' initial focus will be on improving treatment for secondary hyperparathyroidism, which is an unmet need (SHPT). SHPT is a condition in which a disease outside of the parathyroid glands causes all of the parathyroid glands to swell and become hyperactive, producing an excessive amount of parathyroid hormone (PTH).

Pathalys is a clinical biopharmaceutical company that develops therapeutics that improve late-stage chronic kidney disease. Pathalys' initial focus will be on improving treatment for secondary hyperparathyroidism, which is an unmet need (SHPT). SHPT is a condition in which a disease outside of the parathyroid glands causes all of the parathyroid glands to swell and become hyperactive, producing an excessive amount of parathyroid hormone (PTH).

Heartbeat Health, Inc. is a healthcare technology company based in New York that specializes in providing virtual cardiovascular disease prevention and management services. Founded in 2017, it offers a data-driven platform that enables real-time consultations between patients and cardiologists. Through its web-based services, Heartbeat Health facilitates secure communication, allowing patients to receive medical advice, treatment, and dietary consultations from healthcare professionals. The company's focus is on reducing cardiovascular risk and improving patient outcomes by promoting continuous engagement and monitoring of heart health. By leveraging technology, Heartbeat Health aims to enhance the quality of care for patients and support at-risk organizations in managing cardiovascular conditions more effectively.

NephroSant is a diagnostic startup founded by physicians and supported by a team of scientists, engineers, and clinicians. The company focuses on developing a urine-based diagnostic tool that aims to predict and prevent the progression of kidney disease. This innovative tool allows for the quantitative measurement of biomarkers, facilitating the early detection and ongoing monitoring of kidney health. It is particularly beneficial for physicians, as it enables the noninvasive detection of acute rejection in kidney transplant patients, ultimately contributing to improved outcomes in kidney care.

SameSky Health is a provider of multicultural engagement and navigation solutions tailored for health plans, providers, and states. The company specializes in connecting payers, providers, and health systems with diverse Medicare patient populations through a patient engagement platform. This platform offers integrated services that include multi-channel messaging, care navigation, and data insights and consultancy. By addressing the unique needs of culturally diverse populations, SameSky Health aims to enhance patient engagement, reduce unnecessary emergency room visits, and ultimately improve health outcomes and the quality of care provided.

Wellth is a digital health company based in New York that aims to enhance treatment adherence among individuals with chronic conditions. By leveraging behavioral economics, Wellth addresses the barriers that hinder patients from forming healthy habits and effectively managing their diseases. The company operates a mobile application that provides targeted incentive plans, reminders, and information to motivate users to engage in preventive health behaviors. Its platform not only empowers consumers to improve their adherence to medication and care plans but also helps reduce preventable hospitalizations and healthcare costs. Wellth's approach includes proven outcomes demonstrated through randomized controlled trials, making it a valuable solution for insurers and healthcare providers seeking to improve population health. Through its user-friendly application, Wellth supports members in establishing sustainable healthy habits while generating cost savings for payors.